UKJ0 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Targeted Clinical-stage PipelineOpthea's focused biologic program targets VEGF-C/D in combination with anti-VEGF-A for wet AMD and DME, a clearly defined commercial opportunity. This targeted mechanism and indication focus provide durable strategic clarity and potential differentiation versus monotherapy approaches if trials succeed.
Low Financial LeverageEliminating debt materially reduces near-term fixed obligations and interest costs, improving financial flexibility. For a cash-burning clinical-stage biotech, zero debt lowers insolvency risk and preserves the ability to pursue equity, partnership, or milestone-based funding without immediate debt service constraints.
Positive Gross Profit HistoryReporting positive gross profit suggests existing revenue activities have favorable unit economics despite overall losses. If commercialized or partnered, these underlying margins could support scalable profitability and margin expansion, assuming successful transition from development to revenue generation.
Bears Say
Persistent Heavy Cash BurnSustained ~-159M operating cash outflows indicate entrenched negative cash generation requiring continued external funding. This persistent burn limits runway, forces dilutive financings or dependence on deals, and constrains strategic optionality for trials and commercialization over the medium term.
Negative Shareholders' Equity And Shrinking AssetsNegative equity and a sharp asset decline reflect accumulated losses and an eroded capital base, reducing the firm's ability to absorb setbacks. A weakened balance sheet impairs access to non-dilutive capital, worsens leverage perceptions, and increases the probability of future equity issuance or unfavorable partnership terms.
Minimal And Volatile Revenue With Large LossesVolatile, very small revenue and persistent large operating losses typify a pre-commercial biotech reliant on trial success. Lack of stable revenue undermines internal funding capacity and heightens dependency on external financing to progress pivotal studies, creating substantive execution and dilution risk over time.
UKJ0 FAQ
What was Opthea Limited’s price range in the past 12 months?
Opthea Limited lowest stock price was <€0.01 and its highest was €0.32 in the past 12 months.
What is Opthea Limited’s market cap?
Opthea Limited’s market cap is €10.06M.
When is Opthea Limited’s upcoming earnings report date?
Opthea Limited’s upcoming earnings report date is Aug 28, 2026 which is in 35 days.
How were Opthea Limited’s earnings last quarter?
Opthea Limited released its earnings results on Mar 01, 2026. The company reported €0.16 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Opthea Limited overvalued?
According to Wall Street analysts Opthea Limited’s price is currently Overvalued.
Does Opthea Limited pay dividends?
Opthea Limited does not currently pay dividends.
What is Opthea Limited’s EPS estimate?
Opthea Limited’s EPS estimate is 0.
How many shares outstanding does Opthea Limited have?
Opthea Limited has 1,367,978,100 shares outstanding.
What happened to Opthea Limited’s price movement after its last earnings report?
Opthea Limited reported an EPS of €0.16 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Opthea Limited?
Currently, no hedge funds are holding shares in DE:UKJ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opthea Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-83.74%
Trailing 12-Months
Company Description
Opthea Limited
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Cynata Therapeutics Limited
―
Mesoblast Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Recce Pharmaceuticals Ltd.
―